*Results based on adults in a clinical trial who received ZIIHERA + tislelizumab (immunotherapy) + chemotherapy as their first treatment for HER2+ advanced gastroesophageal adenocarcinoma (GEA).
I have plans. And I want to keep them.
ZIIHERA helps people with HER2+ advanced GEA to live longer.
I'm not done yet.
How can a ZIIHERA treatment plan help you?
See the trial resultsClaim your complimentary ZIIHERA
Care Package
ZIIHERA is a targeted treatment for people with HER2+ advanced GEA, or gastroesophageal adenocarcinoma. It is used in combination with chemotherapy, with or without tislelizumab (immunotherapy).
Living with HER2+ advanced GEA is challenging, but you have a strong support team. Understanding your diagnosis and your treatment options can help you feel more confident and in control of your care.